Skip to main content
. 2016 Aug 2;5(4):395–401. doi: 10.3892/mco.2016.973

Figure 2.

Figure 2.

Kaplan-Meier survival curves of all enrolled cases according to the expression status of BAF250a. Progression-free and overall survival curves of BAF250a-deficient expression cases (solid line) and BAF250a-retained cases (dotted line) were produced. (A) The 5-year progression-free survival rate was 59% in BAF250a-deficient expression cases and 68% in BAF150a-retained cases (P=0.24). (B) The 5-year overall survival rate was 49% in BAF250a-deficient expression cases and 67% in BAF150a-retained cases (P=0.43).